Global Urokinase Market COVID-19 Impact Analysis
Since the outbreak of COVID-19 pandemic from past year, each and every market and industry around the globe is affected in a negative way. According to American society of Hematology July 2020, 15-20% of patients suffering from acute pulmonary embolism and deep vein thrombosis require mechanical ventilation and blood clot-busting agents after getting infected by COVID-19 infection. Moreover, According to World Health Organization 2019, it is observed that COVID-19 infection leads to formation of blood clots in patients, thus there is need of blood clot busting agents, when mechanical ventilators are in shortage due to increase in patient population infected by COVID-19 infection.
Request FREE Sample
Urokinase is a thrombolytic drug also known as urokinase-type plasminogen activator, a serine protease present in humans as well as animals. Urokinase is also called as ‘clot-busting drug’, which produces a plasminogen substance that dissolves unwanted blood clots. Urokinase is administrated into vein through intravenous route and urokinase is administered slowly over a period of 12 hours by using a continuous infusion pump.
Global Urokinase Market Drivers
The rising prevalence of pulmonary embolism globally has boosted demand for blood clot-busting agents. For instance, according to National Library of Health in 2018, pulmonary embolism have high prevalence globally with 10 million cases per year. Moreover, usage of urokinase in the treatment of cardiovascular disease is also driving demand for blood clot-busting agents such as urokinase. For instance, in June 2020, Hospital of Zhenghou University started clinical trial on the treatment of minor heart stroke with urokinase thrombolysis, which is expected to complete in 2021. These factors are expected to drive growth of the global urokinase market over the forecast period.
Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/4151
Global Urokinase Market Restraints
Urokinase is contraindicated in cancer patients, as urokinase elevates plasminogen activation systems, which causes tissue invasion leading towards metastasis and causing cancer growth. Moreover, urokinase is also contraindicated in patients suffering from brain tumor and high blood pressure. These factors are expected to restrain growth of the global urokinase market.
Global Urokinase Market Regional Analysis
On basis of region global urokinase market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is having high prevalence of pulmonary embolism and deep vein thrombosis in elder population. For instance, according to the National Library of Medicine report 2018, 600,000 cases of deep vein thrombosis are recorded per year with 100,000 deaths in the U.S. Therefore, increasing prevalence of deep vein thrombosis and pulmonary embolism are driving demand for blood clot busters in the region. For instance, in 2018, Microbix Biosystem Inc, a biologics product manufacturer, entered into an agreement with Toreya Partners LLC for re-launch of kinlytics (urokinase) a clot busting drug in the U.S. market.
In Europe, pharmaceutical companies are focusing on product approvals in field of global urokinase market to strengthen their market share in the region. For instance, in 2019 Syner Medica LTD received approval for marketing of syner-kinase (urokinase) in the U.K. by European Medical Agency.
Global Urokinase Market Key Players
Key players operating in the global urokinase market include Jiangsu Aidea Pharmaceutical Co Ltd, Jiangxi Haoran Bio-Pharma Co., Ltd, Cadila Healthcare Limited, TAJ Pharmaceuticals Limited, Microbix Biosystems Inc, Syner Medica LTD, ImaRx Therapeutics, Inc, and Wilex AG.
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/4151
On the basis of distribution channel, the global urokinase market is segmented into:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
On the basis of Formulation, the global urokinase market is segmented into:
- Urokinase Solution
- Urokinase Powder
On the basis of region, the global urokinase market is segmented into:
- North America
- Latin America
- Asia Pacific
- Middle East
Other Related Reports:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027